Qiagen aims to more than quadruple its COVID-19 reagent production in 6 weeks


Qiagen is looking to steeply ramp up its worldwide production of the RNA test reagents used to perform certain COVID-19 diagnostics.

Previously, the Dutch diagnostics manufacturer turned out enough of the chemical mixture to supply about 1.5 million coronavirus tests per month. Now, Qiagen plans to scale up to support more than 6.5 million tests by the end of April, and more than 10 million per month by the end of June.

By the end of the year, the company hopes to provide for more than 20 million monthly tests through its manufacturing sites in the U.S. and Europe. 

Virtual Event

Virtual Clinical Trials Online

This virtual event will bring together industry experts to discuss the increasing pace of pharmaceutical innovation, the need to maintain data quality and integrity as new technologies are implemented and understand regulatory challenges to ensure compliance.

Qiagen told Politico earlier this month that these materials were on backorder due to sharp increases in the demand for coronavirus testing. Meanwhile, Robert Redfield, head of the Centers for Disease Control and Prevention, testified before Congress late last week saying that testing reagents industry-wide were beginning to go into short supply.

Qiagen’s kits are used to extricate RNA strands from the cells and viruses within a sample, and purify them so they can be sequenced and matched for signs of the novel coronavirus SARS-CoV-2, which causes the pandemic disease COVID-19.

The company’s products are a few of several that can be employed during testing steps for the diagnostic previously developed by the CDC, for example, alongside compatible reagents from Roche and bioMérieux, according to the FDA.

RELATED: Thermo Fisher finally lands Qiagen with $11.5B deal

“Qiagen teams are working 24/7 to address the unprecedented demand for reagents that has emerged to enable testing for COVID-19 in terms of RNA extraction, as well as for production of tests for use on the QIAstat-Dx syndromic testing system,” Qiagen’s interim CEO Thierry Bernard said in a statement.

“We continue to work with our customers around the world to assess their flexibility, timing and quantity needs to support shipping of RNA extraction reagents to the most critical areas,” added Bernard, who also heads the company’s molecular diagnostics business.

Additionally, the company said it expects to receive regulatory clearances in both the U.S. and Europe in the coming days for its coronavirus panel on the QIAstat-Dx respiratory test platform. Qiagen previously received a grant from the U.S. Biomedical Advanced Research and Development Authority, known as BARDA, to support its development.

Suggested Articles

A new Harvard spinout, i2O Therapeutics, hopes to have people with diabetes reach for a bottle of pills, instead of the syringe.

The U.S. federal government has tapped Philips and GM to manufacture hospital ventilators for critical COVID-19 care.

Takeda and CSL Behring have set up an alliance work on an unbranded treatment made from the plasma of patients who have recovered from COVID-19.